Jon Chung

5.4k total citations
109 papers, 2.0k citations indexed

About

Jon Chung is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jon Chung has authored 109 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 42 papers in Cancer Research. Recurrent topics in Jon Chung's work include Cancer Genomics and Diagnostics (40 papers), Lung Cancer Treatments and Mutations (19 papers) and Bladder and Urothelial Cancer Treatments (16 papers). Jon Chung is often cited by papers focused on Cancer Genomics and Diagnostics (40 papers), Lung Cancer Treatments and Mutations (19 papers) and Bladder and Urothelial Cancer Treatments (16 papers). Jon Chung collaborates with scholars based in United States, Italy and United Kingdom. Jon Chung's co-authors include Siraj M. Ali, Jeffrey S. Ross, Vincent A. Miller, Fred Bunz, Alexa B. Schrock, Garrett M. Frampton, Andrea Necchi, Philip J. Stephens, James Suh and Sumanta K. Pal and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jon Chung

106 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Chung United States 25 1.0k 765 720 677 424 109 2.0k
Luca Emanuele Pollina Italy 22 1.1k 1.1× 750 1.0× 417 0.6× 566 0.8× 418 1.0× 63 2.1k
Sherri Z. Millis United States 25 1.1k 1.1× 772 1.0× 852 1.2× 421 0.6× 435 1.0× 93 2.3k
Julie W. Reeser United States 14 966 0.9× 926 1.2× 609 0.8× 782 1.2× 404 1.0× 30 2.2k
Maria Giulia Cangi Italy 21 878 0.9× 914 1.2× 479 0.7× 356 0.5× 303 0.7× 55 2.2k
Kathleen Cieply United States 30 857 0.8× 940 1.2× 737 1.0× 400 0.6× 695 1.6× 58 2.6k
Linda Kapusta Canada 16 1.1k 1.1× 902 1.2× 443 0.6× 409 0.6× 306 0.7× 23 2.1k
An Na Seo South Korea 27 1.4k 1.4× 803 1.0× 681 0.9× 555 0.8× 350 0.8× 107 2.5k
Marta Salido Spain 27 1.3k 1.3× 709 0.9× 758 1.1× 683 1.0× 249 0.6× 111 2.5k
Takashi Sakatani Japan 20 707 0.7× 1.0k 1.3× 297 0.4× 445 0.7× 313 0.7× 72 1.9k

Countries citing papers authored by Jon Chung

Since Specialization
Citations

This map shows the geographic impact of Jon Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Chung more than expected).

Fields of papers citing papers by Jon Chung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Chung. The network helps show where Jon Chung may publish in the future.

Co-authorship network of co-authors of Jon Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Chung. A scholar is included among the top collaborators of Jon Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Chung. Jon Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Joyce F., Stéphanie Gaillard, Andrea E. Wahner Hendrickson, et al.. (2024). Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. 8(8). e2300693–e2300693. 6 indexed citations
2.
Sivakumar, Smruthy, Dexter X. Jin, Hanna Tukachinsky, et al.. (2022). Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nature Communications. 13(1). 7495–7495. 26 indexed citations
3.
Lee, Jessica, Mehlika Hazar-Rethinam, Brennan Decker, et al.. (2021). The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clinical Cancer Research. 28(4). 728–737. 28 indexed citations
4.
Bratslavsky, Gennady, Joseph M Jacob, Thomas Sanford, et al.. (2021). Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 39(6). 367.e1–367.e5. 12 indexed citations
5.
Mao, Pingping, Ofir Cohen, Kailey J. Kowalski, et al.. (2020). Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research. 26(22). 5974–5989. 90 indexed citations
6.
Madison, Russell W., Sumati Gupta, Yasir Y. Elamin, et al.. (2020). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. British Journal of Urology. 125(5). 739–746. 11 indexed citations
7.
Dizman, Nazlı, Siraj M. Ali, Huiqing Wu, et al.. (2019). Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. Clinical Genitourinary Cancer. 18(3). e289–e292. 8 indexed citations
8.
Necchi, Andrea, Gennady Bratslavsky, Oleg Shapiro, et al.. (2019). Genomic features of metastatic testicular sex cord stromal tumors.. Journal of Clinical Oncology. 37(7_suppl). 532–532. 11 indexed citations
9.
Schrock, Alexa B., Dean C. Pavlick, Samuel J. Klempner, et al.. (2018). Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research. 24(8). 1881–1890. 54 indexed citations
10.
Pavlick, Dean C., Jon Chung, Julia A. Elvin, et al.. (2017). Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types. Annals of Oncology. 28. v595–v595. 4 indexed citations
11.
Ikeda, Sadakatsu, Laurie M. Gay, Dean C. Pavlick, et al.. (2017). Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types. Annals of Oncology. 28. x1–x1. 3 indexed citations
12.
Ross, Jeffrey S., Pierre Vanden Borre, Nava Almog, et al.. (2017). Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas. Annals of Oncology. 28. v595–v596. 6 indexed citations
13.
Gornstein, Erica, Jon Chung, Laurie M. Gay, et al.. (2017). BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clinical Breast Cancer. 18(2). 184–188. 36 indexed citations
14.
Sheehan, Christine E., Laurie M. Gay, Julia A. Elvin, et al.. (2017). Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment. 162(3). 597–602. 36 indexed citations
15.
Ali, Siraj M., Jessica Watson, Kai Wang, et al.. (2016). A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. Case Reports in Oncology. 9(1). 112–118. 2 indexed citations
16.
Bai, Ren-Yuan, Jon Chung, Alexandra Borodovsky, et al.. (2014). Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor. Molecular Cancer Therapeutics. 14(1). 3–13. 75 indexed citations
17.
Heo, Su Jin, Jon Chung, Woo Jin Hyung, et al.. (2014). 44 Metformin and its impact on gastric cancer patients survival after gastrectomy. European Journal of Cancer. 50. 20–20. 1 indexed citations
18.
Chung, Jon, Siraj M. Ali, Laurie M. Gay, et al.. (2014). A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib. Case Reports in Oncology. 7(3). 628–632. 10 indexed citations
19.
Wilsker, Deborah, Jon Chung, Iván Pradilla, et al.. (2011). Targeted Mutations in the ATR Pathway Define Agent-Specific Requirements for Cancer Cell Growth and Survival. Molecular Cancer Therapeutics. 11(1). 98–107. 4 indexed citations
20.
Chung, Jon & Fred Bunz. (2010). Cdk2 Is Required for p53-Independent G2/M Checkpoint Control. PLoS Genetics. 6(2). e1000863–e1000863. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luca Emanuele Pollina Breakdown of academic impact, for papers by Sherri Z. Millis Breakdown of academic impact, for papers by Julie W. Reeser Breakdown of academic impact, for papers by Maria Giulia Cangi Breakdown of academic impact, for papers by Kathleen Cieply Breakdown of academic impact, for papers by Linda Kapusta Breakdown of academic impact, for papers by An Na Seo Breakdown of academic impact, for papers by Marta Salido Breakdown of academic impact, for papers by Takashi Sakatani
Rankless by CCL
2026